A novel method for inhibiting cancer metastasis and invasion by regulating the Lin7C-CASK-βcatenin-network.

• Project/Area Number: 21390531
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Chiba University
• Principal Investigator: SAKAMOTO Yosuke 千葉大学, 医学部・附属病院, 助教 (50451745)
• Co-Investigator(Kenkyū-buntansha): SAKAMOTO Yosuke 千葉大学, 医学部附属病院, 助教 (50451745) ; TANZAWA Hideki 千葉大学, 大学院・医学研究院, 教授 (50236775)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000); Fiscal Year 2011: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000); Fiscal Year 2010: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000); Fiscal Year 2009: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
• Keywords: 浸潤転移能 / Lin7C-CASK-βcateninネットワーク / HTR2C遺伝子 / トランスレーショナルリサーチ / 癌転移抑制法 / 癌浸潤抑制法 / Lin7C / β-catenin

Research Abstract

The aim of this study was to develop a new method of inhibiting the invasion and metastasis of oral squamous cell carcinoma (OSCC) through the activating Lin7C-CASK-βcatenin (LCB) pathway. In Lin7C-overexpressed OSCC cells, CASK andβcatenin levels are significantly higher than that in Mock-transfected cells. In addition, we identified HTR2C in some molecules of upstream of LCB pathway by the Ingenuity Pathway Analysis. We demonstrated that the specific HTR2C inhibitor closely related to LCB pathway, and therefore might be a therapeutic tool for cancer invasion and metastasis.

Research Products

• [Presentation] 口腔癌転移抑制候補タンパクLin-7C/VEL13/MALS-3の同定と包括的機能解析 (2010)
  • Author(s): 鵜澤一弘, 恩田健志, 佐久間健太郎, 大和地正信, 石上享嗣, 伏見一章, 中島大, 肥後盛洋, 笠松厚志, 坂本洋右, 椎葉正史, 武川寛樹, 横江秀隆, 柴原孝彦, 丹沢秀樹
  • Organizer: 第54回日本口腔外科学会総会
  • Place of Presentation: 札幌